RxDoctor Payments Data

Leila Rubio, MD

Family Medicine · Sweetwater, TXNPI 1194253948

Payments from drug & device makers

$574in general payments, 2019–2025

Across 22 payments — averaging $26.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$123
  • Sobi, Inc$99
  • AstraZeneca$75
  • Novartis$74
  • AbbVie$46
  • Abbott$35
  • plus $122 from 7 others

What the payments were for

  • Food & beverage$574100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$574 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$28,171
Medicare patients
411
Services billed
852

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide97$105,271
OzempicSemaglutide74$79,592
TrulicityDulaglutide63$64,479
EliquisApixaban69$63,360
RybelsusSemaglutide38$52,433
LinzessLinaclotide70$50,510
Tresiba Flextouch U-200Insulin Degludec44$31,544
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$29,096
XareltoRivaroxaban25$23,594
FarxigaDapagliflozin Propanediol35$22,632
JanuviaSitagliptin Phosphate31$21,119
JardianceEmpagliflozin19$20,336
MyrbetriqMirabegron30$17,541
SymbicortBudesonide/Formoterol Fumarate45$14,303
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$8,858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$13$169,750160 claims
Novo NordiskOzempic, Rybelsus$14$132,026112 claims
AbbVieLinzess, Creon$46$56,23485 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$123$37,87365 claims
AstraZenecaFarxiga, Symbicort$75$36,93580 claims
Johnson & JohnsonXarelto$13$23,59425 claims
Boehringer IngelheimJardiance$33$20,33619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Sweetwater

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →